Shots:

• The BLA submission is based on study assessing RVT-802 in 93 patients with Pediatric Congenital Athymia
• The study resulted in survival rates of (76%- 75%) as estimated with Kaplan-Meier @1-2 yrs. and for the patients surviving 12 mos. post-treatment has a possibility of 93% probability of surviving 10 years post-treatment
• RVT-802 is a one-time tissue-based regenerative therapy targeted for pediatric congenital athymia and has also received FDA’s PR for same. In 2016- Enzyvant entered into an exclusive WW license agreement with Duke University to develop RVT-802

Click here to read full press release/ article | Ref: Enzyvant | Image: ID Works Global